Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Henry Schein (HSIC) and NovoCure (NVCR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Henry Schein (HSIC – Research Report) and NovoCure (NVCR – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen (AMGN)
Leerink Partners analyst David Risinger maintained a Hold rating on Amgen today. The company’s shares closed last Monday at $325.54.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $346.20, implying a 5.4% upside from current levels. In a report released yesterday, Truist Financial also maintained a Hold rating on the stock.
See the top stocks recommended by analysts >>
Henry Schein (HSIC)
In a report released today, Michael Cherny from Leerink Partners maintained a Hold rating on Henry Schein. The company’s shares closed last Monday at $76.13.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $77.00, which is a 1.7% upside from current levels. In a report released yesterday, TipRanks – Google also reiterated a Hold rating on the stock with a $87.00 price target.
NovoCure (NVCR)
Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure today and set a price target of $24.00. The company’s shares closed last Monday at $14.18, close to its 52-week low of $11.70.
According to TipRanks.com, Chang is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NovoCure with a $24.42 average price target, which is a 62.7% upside from current levels. In a report issued on January 5, Evercore ISI also maintained a Buy rating on the stock with a $20.00 price target.
